Hirsch, Fred R. http://orcid.org/0000-0002-6885-1894
Kim, Chul
Funding for this research was provided by:
Pfizer
Article History
Received: 23 August 2023
Accepted: 6 March 2024
First Online: 27 March 2024
Declarations
:
: Fred Hirsch reports participation on advisory boards for Amgen, AstraZeneca, Blueprint, BMS, G1 Therapeutics, Genentech, Merus, NextCure, Novartis, Novocure, Regeneron, and Sanofi. Chul Kim reports institutional grants from AstraZeneca, BMS, Daiichi Sankyo, Debiopharm, Genentech, Janssen, Karyopharm, Lyell Immunopharma, Novartis, and Regeneron; and consulting fees from Arcus Biosciences, AstraZeneca, Daiichi Sankyo, Diffusion Pharmaceuticals, Eisai, Janssen, Jazz Pharmaceuticals, Mirati, Novartis, PierianDx, Regeneron, and Sanofi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.